GB922027A - Poliomyelitis vaccine production - Google Patents

Poliomyelitis vaccine production

Info

Publication number
GB922027A
GB922027A GB43540/59A GB4354059A GB922027A GB 922027 A GB922027 A GB 922027A GB 43540/59 A GB43540/59 A GB 43540/59A GB 4354059 A GB4354059 A GB 4354059A GB 922027 A GB922027 A GB 922027A
Authority
GB
United Kingdom
Prior art keywords
virus
less
live
aluminium phosphate
antigenic material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB43540/59A
Inventor
Karl Heinz Fantes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB43540/59A priority Critical patent/GB922027A/en
Priority to BE598450A priority patent/BE598450A/en
Publication of GB922027A publication Critical patent/GB922027A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Live poliomyelitis virus and/or antigenic material derived therefrom is purified and/or concentrated by adsorbing the live virus and/or antigenic material at a pH of less than 7 from an aqueous medium on to aluminium phosphate and subsequently eluting the live virus and/or antigenic material therefrom by means of an aqueous medium at a pH greater than 7. The pH for adsorption depends upon the virus type and quantity of aluminium phosphate used. For Type I virus, a pH of less than 5.8 and preferably 4.7 to 5.2 is used. For Types II and III a pH of less than 6.8 and preferably 5.0 to 5.5 is used. In general the pH should be at least 4.5 for absorption. The aluminium phosphate is used in concentrations of 0.05-8 mg/ml. and preferably 0.1 to 4 mg/ml. Elution is preferably at pH 8 to 11. Suitable eluants are aqueous solutions of alkali metal and alkaline earth metal hydroxides, carbonates and bicarbonates and aqueous solutions of disodium or dipotassium hydrogen phosphate. Process may be applied to the virus-containing liquid after the virus has been inactivated. Vaccines are produced from the material so formed.
GB43540/59A 1959-12-22 1959-12-22 Poliomyelitis vaccine production Expired GB922027A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB43540/59A GB922027A (en) 1959-12-22 1959-12-22 Poliomyelitis vaccine production
BE598450A BE598450A (en) 1959-12-22 1960-12-22 Vaccine manufacturing process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB43540/59A GB922027A (en) 1959-12-22 1959-12-22 Poliomyelitis vaccine production

Publications (1)

Publication Number Publication Date
GB922027A true GB922027A (en) 1963-03-27

Family

ID=10429217

Family Applications (1)

Application Number Title Priority Date Filing Date
GB43540/59A Expired GB922027A (en) 1959-12-22 1959-12-22 Poliomyelitis vaccine production

Country Status (2)

Country Link
BE (1) BE598450A (en)
GB (1) GB922027A (en)

Also Published As

Publication number Publication date
BE598450A (en) 1961-04-14

Similar Documents

Publication Publication Date Title
JPS52100500A (en) Purification and concentration of aqueous stevioside extract
GB960850A (en) Measles virus vaccine
GB1055896A (en) Silica adsorbents in interferon purification and/or concentration
GB902639A (en) Method of purification of streptokinase
GB922027A (en) Poliomyelitis vaccine production
GB980227A (en) Purification and/or concentration of material containing interferon
JPS5236188A (en) Preparation of heavy metal ion adsorbent
JPS5219900A (en) Method of processing radioactive waste liquor
GB1010919A (en)
JPS5230055A (en) Adsorption treatment method of waste water by activated carbon
JPS51122690A (en) Method of separating and condensing oxygen
JPS523581A (en) Permeable membrane forming process
ES275578A1 (en) A procedure to separate a less concentrated solution from a relatively more concentrated solution (Machine-translation by Google Translate, not legally binding)
JPS5257129A (en) Process for hydroquinone
GB949400A (en) Poliomyelitis vaccines
DE3063118D1 (en) Process for the preparation of ergotamine and of alcaloids of the ergotoxine group
GB865042A (en) Removal of radio-active strontium and cesium from milk
JPS5239615A (en) Process for preparation of saturated fatty acids
NL7408579A (en) Vaccine against respiratory infections esp in horses - contg an adsorbed, killed suspension of reovirus in water
JPS528859A (en) Double needle system
JPS5270279A (en) Brake apparatus for body of revolution
JPS5228490A (en) Uranium adsorbent
JPS5228489A (en) Uranium adsorbent
JPS51137296A (en) Tag boat having a towing equipment of adsorption type
JPS51111635A (en) Fail-safe system